PRESCRIBING SGLT2 INHIBITORS IN ACUTE HEART FAILURE: CONSIDERATIONS FOR DYSGLYCEMIA STATUS, HEART FAILURE PHENOTYPE, AND KIDNEY FUNCTION ArticleMedovchshikov V.V., Yeshniyazov N., Khasanova E., Zholdin B., Kurmanalina G., Kushimova D., Tleumagambetova B., Amanova A., Kobalava Z.European Journal of Heart Failure. Том 26. 2024. С. 591-592
CARDIOVASCULAR DISEASES AND TYPE 2 DIABETES MELLITUS: HIGH HEART FAILURE RISK AND LOW RATE CONTRAINDICATIONS TO SGLT2I ArticleMedovchshikov V.V., Yeshniyazov N., Khasanova E., Zholdin B., Kurmanalina G., Amanova A., Kobalava Z.European Journal of Heart Failure. Том 26. 2024. С. 563-563
THE INCIDENCE OF THE FIRST ONSET DIAGNOSED TYPE 2 DIABETES MELLITUS IN PATIENTS WITH CARDIOVASCULAR DISEASES ArticleMedovchshikov V.V., Yeshniyazov N.B., Tereshchenko E.A., Khasanova E.R., Kobalava Z.D.European Journal of Heart Failure. Том 21. 2019. С. 135-135
THE MODERN PARADIGM OF PATHOPHYSIOLOGY, PREVENTION AND TREATMENT OF HEART FAILURE IN TYPE 2 DIABETES MELLITUS ArticleKobalava Z.D., Medovchshikov V.V., Yeshniyazov N.B., Khasanova E.R.Российский кардиологический журнал. Том 24. 2019. С. 98-111
THE INCIDENCE OF CHRONIC HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ArticleYeshniyazov N.B., Medovchshikov V.V., Tereshchenko E.A., Khasanova E.R., Kobalava Z.D.European Journal of Heart Failure. Том 21. 2019. С. 253-253